{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:41:51Z","timestamp":1763642511625},"reference-count":79,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2018.7015","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T07:55:39Z","timestamp":1543305339000},"source":"Crossref","is-referenced-by-count":13,"title":["Mesothelin\u2011targeted second generation CAR\u2011T cells inhibit growth of mesothelin\u2011expressing tumors in\ufffdvivo"],"prefix":"10.3892","author":[{"given":"Lin","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Lu","sequence":"additional","affiliation":[{"name":"Central Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"key":"key20200713115745_b1-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.20132","article-title":"Immunotherapy of cancer in 2012","volume":"62","author":"Kirkwood","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"key20200713115745_b2-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions, et al The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20200713115745_b3-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1097\/JTO.0000000000000379","article-title":"NSCLC and HER2: Between lights and shadows","volume":"9","author":"Ricciardi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"key20200713115745_b4-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/1758834014567469","article-title":"Nivolumab in melanoma: Latest evidence and clinical potential","volume":"7","author":"Johnson","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"key20200713115745_b5-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/resp.12490","article-title":"Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)","volume":"20","author":"Kumarakulasinghe","year":"2015","journal-title":"Respirology"},{"key":"key20200713115745_b6-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1136\/oem.2003.010165","article-title":"Changing trends in US mesothelioma incidence","volume":"61","author":"Weill","year":"2004","journal-title":"Occup Environ Med"},{"key":"key20200713115745_b7-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N Engl J Med"},{"key":"key20200713115745_b8-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"key20200713115745_b9-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20200713115745_b10-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: Moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat Med"},{"key":"key20200713115745_b11-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1189\/jlb.0513293","article-title":"At the bedside: Adoptive cell therapy for melanoma-clinical development","volume":"95","author":"Weber","year":"2014","journal-title":"J Leukoc Biol"},{"key":"key20200713115745_b12-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"key20200713115745_b13-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713115745_b14-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I Trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20200713115745_b15-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"key20200713115745_b16-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Glienke","year":"2015","journal-title":"Front Pharmacol"},{"key":"key20200713115745_b17-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res"},{"key":"key20200713115745_b18-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: A new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"key20200713115745_b19-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jcv.2015.04.019","article-title":"A simplified Sanger sequencing method for full genome sequencing of multiple subtypes of human influenza A viruses","volume":"68","author":"Deng","year":"2015","journal-title":"J Clin Virol"},{"key":"key20200713115745_b20-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","article-title":"Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy","volume":"32","author":"Hollyman","year":"2009","journal-title":"J Immunother"},{"key":"key20200713115745_b21-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20200713115745_b22-etm-0-0-7015","doi-asserted-by":"crossref","first-page":"19740","DOI":"10.1016\/S0021-9258(19)47174-3","article-title":"Protein L: An immunoglobulin light chain-binding bacterial protein. Characterization of binding and physicochemical properties","volume":"264","author":"Akerstrom","year":"1989","journal-title":"J Biol Chem"},{"key":"key20200713115745_b23-etm-0-0-7015","first-page":"221","article-title":"Subcloning strategies and protocols","volume":"58","author":"Taghian","year":"1996","journal-title":"Methods Mol Biol"},{"key":"key20200713115745_b24-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"key20200713115745_b25-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20200713115745_b26-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/bjc.1972.21","article-title":"Eighty years of immunotherapy: A review of immunological methods used for the treatment of human cancer","volume":"26","author":"Currie","year":"1972","journal-title":"Br J Cancer"},{"key":"key20200713115745_b27-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: The first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"key20200713115745_b28-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"key20200713115745_b29-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00262-012-1311-8","article-title":"Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients","volume":"62","author":"Yang","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713115745_b30-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"e93591","DOI":"10.1371\/journal.pone.0093591","article-title":"Dendritic cells decreased the concomitant expanded tregs and tregs related IL-35 in cytokine-induced killer cells and increased their cytotoxicity against leukemia cells","volume":"9","author":"Pan","year":"2014","journal-title":"PLoS One"},{"key":"key20200713115745_b31-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"key20200713115745_b32-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"e27572","DOI":"10.4161\/onci.27572","article-title":"\u03b3\u03b4 T cells for cancer immunotherapy: A systematic review of clinical trials","volume":"3","author":"Fisher","year":"2014","journal-title":"OncoImmunology"},{"key":"key20200713115745_b33-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/86297","article-title":"A fresh look at tumor immunosurveillance and immunotherapy","volume":"2","author":"Smyth","year":"2001","journal-title":"Nat Immunol"},{"key":"key20200713115745_b34-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1535-6108(03)00113-2","article-title":"Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction","volume":"3","author":"Ho","year":"2003","journal-title":"Cancer Cell"},{"key":"key20200713115745_b35-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"key20200713115745_b36-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713115745_b37-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"key20200713115745_b38-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1182\/blood-2007-08-108050","article-title":"CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85\/p110 heterodimer","volume":"111","author":"Gar\u00e7on","year":"2008","journal-title":"Blood"},{"key":"key20200713115745_b39-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: The promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"key20200713115745_b40-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"key":"key20200713115745_b41-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/v3020132","article-title":"The inside out of lentiviral vectors","volume":"3","author":"Durand","year":"2011","journal-title":"Viruses"},{"key":"key20200713115745_b42-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat Biotechnol"},{"key":"key20200713115745_b43-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol"},{"key":"key20200713115745_b44-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bcmd.2004.03.003","article-title":"Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies","volume":"33","author":"Cooper","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"key20200713115745_b45-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20200713115745_b46-etm-0-0-7015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V126.23.183.183","article-title":"Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","volume":"126","author":"Schuster","year":"2015","journal-title":"Blood"},{"key":"key20200713115745_b47-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200713115745_b48-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J Immunother Cancer"},{"key":"key20200713115745_b49-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20200713115745_b50-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol Ther"},{"key":"key20200713115745_b51-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"key20200713115745_b52-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2018.05.009","article-title":"Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials","volume":"369","author":"Arabi","year":"2018","journal-title":"Exp Cell Res"},{"key":"key20200713115745_b53-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1034\/j.1600-065X.2002.18810.x","article-title":"Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: Identification of a tumor-associated antigen","volume":"188","author":"Mami-Chouaib","year":"2002","journal-title":"Immunol Rev"},{"key":"key20200713115745_b54-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"key20200713115745_b55-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/1535-7163.MCT-07-0483","article-title":"Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer","volume":"7","author":"Li","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"key20200713115745_b56-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1158\/1078-0432.CCR-06-2161","article-title":"Mesothelin expression in human lung cancer","volume":"13","author":"Ho","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20200713115745_b57-etm-0-0-7015","first-page":"4721","article-title":"Serum mesothelin in epithelial ovarian carcinoma: A new screening marker and prognostic factor","volume":"26","author":"Huang","year":"2006","journal-title":"Anticancer Res"},{"key":"key20200713115745_b58-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4132\/jptm.2016.11.18","article-title":"Mesothelin expression in gastric adenocarcinoma and its relation to clinical outcomes","volume":"51","author":"Han","year":"2017","journal-title":"J Pathol Transl Med"},{"key":"key20200713115745_b59-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"11694","DOI":"10.18632\/oncotarget.3429","article-title":"High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis","volume":"6","author":"Thomas","year":"2015","journal-title":"Oncotarget"},{"key":"key20200713115745_b60-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to TNF-\u03b1-induced apoptosis through Akt\/PI3K\/NF-\u03baB activation and IL-6\/Mcl-1 overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol Cancer"},{"key":"key20200713115745_b61-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1042\/BJ20110282","article-title":"Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways","volume":"442","author":"Chang","year":"2012","journal-title":"Biochem J"},{"key":"key20200713115745_b62-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1042\/BJ20082196","article-title":"Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway","volume":"424","author":"Chang","year":"2009","journal-title":"Biochem J"},{"key":"key20200713115745_b63-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20200713115745_b64-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"key20200713115745_b65-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"key":"key20200713115745_b66-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.11.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"key20200713115745_b67-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"key20200713115745_b68-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.1229620","article-title":"Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection","volume":"338","author":"Paley","year":"2012","journal-title":"Science"},{"key":"key20200713115745_b69-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"key20200713115745_b70-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1189\/jlb.1212631","article-title":"At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy","volume":"94","author":"Callahan","year":"2013","journal-title":"J Leukoc Biol"},{"key":"key20200713115745_b71-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"key20200713115745_b72-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R 2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20200713115745_b73-etm-0-0-7015","first-page":"1","article-title":"Adoptive T cell therapies for glioblastoma","volume":"1","author":"Gomez","year":"2015","journal-title":"J Cancer Clin Trials"},{"key":"key20200713115745_b74-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat Med"},{"key":"key20200713115745_b75-etm-0-0-7015","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood.V126.23.2046.2046","article-title":"First clinical application of talen engineered universal car19 T cells in B-ALL","volume":"126","author":"Qasim","year":"2015","journal-title":"Blood"},{"key":"key20200713115745_b76-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.gene.2015.05.065","article-title":"HEK293 in cell biology and cancer research: Phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution","volume":"569","author":"Stepanenko","year":"2015","journal-title":"Gene"},{"key":"key20200713115745_b77-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1182\/blood-2010-01-043737","article-title":"Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor","volume":"116","author":"Jena","year":"2010","journal-title":"Blood"},{"key":"key20200713115745_b78-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1158\/0008-5472.CAN-07-5600","article-title":"Redirecting specificity of T-cell populations for CD19 using the sleeping beauty system","volume":"68","author":"Singh","year":"2008","journal-title":"Cancer Res"},{"key":"key20200713115745_b79-etm-0-0-7015","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1073\/pnas.1524193113","article-title":"Versatile strategy for controlling the specificity and activity of engineered T cells","volume":"113","author":"Ma","year":"2016","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T23:05:06Z","timestamp":1662505506000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2018.7015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":79,"URL":"https:\/\/doi.org\/10.3892\/etm.2018.7015","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,27]]}}}